

RECEIVED 1635
JUL 26 2001

TECH CENTER 1800/2000

Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000. OMB 0651-0048
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/283,431	
	Filing Date	April 1, 1999	
	First Named Inventor	Zhou, et al.	
	Group Art Unit	1635	
	Examiner Name	K. Lacourciere	
Total Number of Pages in This Submission	9	Attorney Docket Number	47508.423


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Postcard
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Ann-Louise Kerner, Ph.D., Reg. No. 33,523
Signature	
Date	July 19, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 07/19/01			
Typed or printed name	Sharon R. Matthews		
Signature		Date	07/19/01

+ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JUL 26 2001
TECH CENTER 1600/2900
#17/D
BP
7-27-9



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Docket No. 47508.423)

In re Application of: Zhou, et al.) Group Art Unit: 1635
Serial No.: 09/283,431) Examiner: K. Lacourciere
Filing Date: April 1, 1999)
Title: MIXED BACKBONE OLIGONUCLEOTIDES CONTAINING
POPS BLOCKS TO OBTAIN REDUCED PHOSPHOROTHIOATE
CONTENT

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on the date set forth below.

Date: 7/19/01

By: Sharon R. Matthews
Sharon R. Matthews

Commissioner for Patents
Washington, DC 20231

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.111

Dear Sir:

In response to the Office Action dated April 20, 2001, please amend the above-referenced patent application as follows:

In the claims:

- Sub E1
A
4. (Amended) A hybrid oligonucleotide consisting of one or more deoxyribonucleotide POPS blocks and one or more regions of 2'-O-substituted ribonucleotides,